Platelet-activating Factor Receptor (PAFR) Antagonist

Platelet-activating Factor Receptor (PAFR) Antagonists (43):

Cat. No.	Product Name	Effect	Purity

HY-N0784

Ginkgolide B	Antagonist	99.96%
Ginkgolide B (BN-52021), a terpene lactone, is a potent platelet activating factor antagonist. Ginkgolide B protects endothelial cells via the activation of PXR from injuries induced by xeno- and endobiotics. Ginkgolide B can pass through the brain-blood barrier. Ginkgolide B has anti-oxidant, anti-inflammatory, anti-tumor, and anti-apoptotic activity. Ginkgolide B has marked neuroprotective effects against ischemia-induced impairments.

HY-108634

Apafant	Antagonist	99.96%
Apafant (WEB 2086), a chemical probe, is a potent platelet-activating factor (PAF) antagonist, inhibits PAF binding to human PAF receptors with a K_i of 9.9 nM. Apafant increases the gene expression of PAF-r, α-globin, β-globin, decreases the c-myb gene expression. Apafant shows a protective effect on alkyl-PAF-mediated lethalit.

HY-N2071

Cedrol	Antagonist	99.76%
Cedrol is a potent competitive inhibitor of cytochrome P-450(CYP) enzyme. Cedrol plays an anticancer role by inducing cell cycle arrest and Caspase-dependent apoptosis. Cedrol acts as a neutrophil agonist that can desensitize cells to subsequent stimulation of N-formyl peptides. Cedrol prevents neuropathic pain caused by chronic contractile injury by inhibiting oxidative stress and inflammation. In addition, Cedrol has antibacterial, hair loss prevention and anti-anxiety properties.

HY-106899

MK 287	Antagonist
MK 287 is a potent, selective and orally active antagonist of platelet-activating factor receptor (PAFR). MK 287 can inhibit [3H]C18-PAF binding to human platelet, polymorphonuclear leukocyte (PMN) and lung membranes with K1 values of 6.1, 3.2, and 5.49 nM, respectively. MK 287 can inhibit PAF-induced aggregation of platelets in plasma or gel-filtered platelets and elastase release from PMNs with ED₅₀ values of 56, 1.5 and 4.4 nM. MK 287 can be used for the research of cardiovascular disease, such as thrombosis.

HY-116435

Sch-40338	Antagonist
Sch-40338 is a dual antagonist of platelet-activating factor (PAF) and histamine with an IC₅₀ of 0.59 μM (PAF-induced platelet aggregation) and a K_i of 5.4 μM (Histamine H₁ receptor binding). Sch-40338 can be used for the study of allergic disease.

HY-114745

MoTP	Antagonist	99.76%
MoTP is a specific platelet activating factor receptor antagonist and can induce melanocyte ablation. MoTP can be used for the research of cancer.

HY-N10663

Kadsurenone	Antagonist	99.78%
Kadsurenone is a lignan with specific antagonistic activity against platelet-activating factor. Kadsurenone can be derived from the stem of Piper kadsura.

HY-N7343

Pregomisin	Antagonist	99.87%
Pregomisin is a natural compound isolated from the fruits of Schizandra chinensis Baill. Pregomisin showed PAF antagonistic activity and the IC₅₀ values were 48 μM.

HY-163101

CP-96021	Antagonist	98.04%
CP-96021 is a potent and orally available leukotriene D₄ (LTD₄ K_i=34 μM) / platelet activating factor (PAF K_i=37 μM) receptor antagonist. CP-96021 has antagonist capable of simultaneously targeting two different inflammatory mediators, LTD₄ and PAF. CP-96021 shows high specificity for α1, α2, β, dopamine-2, adenosine 1, 5-HT1, H1, muscarine, μ opioid, and GABA receptors, all expressing IC₅₀ values greater than 10 μM. CP-96021 can be used to study the pathogenesis of many inflammatory diseases such as asthma.

HY-N0784R

Ginkgolide B (Standard)	Antagonist
Ginkgolide B (Standard) is the analytical standard of Ginkgolide B. This product is intended for research and analytical applications. Ginkgolide B (BN-52021), a terpene lactone, is a potent platelet activating factor antagonist. Ginkgolide B protects endothelial cells via the activation of PXR from injuries induced by xeno- and endobiotics. Ginkgolide B can pass through the brain-blood barrier. Ginkgolide B has anti-oxidant, anti-inflammatory, anti-tumor, and anti-apoptotic activity. Ginkgolide B has marked neuroprotective effects against ischemia-induced impairments.

HY-N12995

α-Bulnesene	Antagonist
α-Bulnesene is a novel PAF receptor antagonist with the IC₅₀ of 17.62 μM. α-Bulnesene can be isolated from Pogostemon cablin. α-Bulnesene shows inhibitory effect on platelet-activating factor and arachidonic acid induced rabbit platelet aggregation.

HY-19126

CL-184005	Antagonist
CL-184005 is an antagonist for platelet-activating factor (PAF), that inhibits the PAF-induced platelet aggregation with IC₅₀ of 600 nM and 510 nM, in human and rabbit platelet-rich plasma. CL-184005 protects the rats from endotoxin-induced gastrointestinal damage and hypotension. CL-184005 exhibits potential attenuating Gram-negative bacterial sepsis.

HY-171253

Clotizolam	Antagonist
Clotizolam is a thienobenzodiazepine derivative that has antagonistic activity against platelet-activating factor (PAF). Clotizolam possesses sedative, anxiolytic, anticonvulsant,and muscle relaxant effects.

HY-N3436

Kadsurin A	Antagonist
Kadsurin A is a new lignan can be isolated from Piper futokadsura. Kadsurin A is a platelet activating factor (PAF) receptor antagonist that weakly inhibits the binding of PAF to its receptor.

HY-136791

BN52115	Antagonist
BN 52115, a platelet-activating factor antagonist, has demonstrated the ability to mitigate bronchopulmonary changes in vivo.

HY-106833

SDZ-62-434 free base	Antagonist
SDZ-62-434 (free base) is a platelet-activating factor (PAF) antagonist. SDZ-62-434 (free base) has antiproliferative activity in human solid and haematological malignancies.

HY-132190

Hexanolamino PAF C-16	Antagonist
Hexanolamino PAF C-16 (1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine) is a Platelet-activating Factor Receptor (PAFR) Modulator with partial agonist activity. Hexanolamino PAF C-16 induces platelet aggregation and macrophage production but fails to increase [Ca2+]i in platelets, suggesting that PAF receptors may interact with PAF receptors through Ca²⁺-dependent and -independent pathways. Related to platelet aggregation.

HY-121377

Epiyangambin	Antagonist
Epiyangambin is a competitive platelet activating factor receptor (PAF) antagonist that dose-dependently inhibits PAF-induced platelet aggregation. Epiyangambin also inhibits the growth of human colon cancer cells (SW480 cells).

HY-19125

BN-50726	Antagonist
BN-50726 is a potent platelet-activating factor (PAF) receptor antagonist. BN-50726 inhibits PAF-induced effects (e.g., [3H]-serotonin release and hypotension) (IC₅₀= 5.40 nM). BN-50726 is promising for research of PAF-mediated pathological processes (e.g., inflammation, anaphylaxis, hypotension).

HY-132210

rel-(2R,4R)-2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane	Antagonist
rel-(2R,4R)-2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane (compound 6) is a platelet-activating factor receptor (PAFR) antagonist with a K_i of 0.3 µM.

Name
Email *

	Sorry, but the email address you supplied was invalid.